New Initiatives:

ATR-COSF: Expansion into Cosmetic Ingredients

One of the most exciting initiatives enabled by the March financing is ATR-COSF, a recombinant filaggrin protein program designed for the cosmetic ingredient market.

ATR-COSF originated from our ATR-01 research program, which was initially developing a live biotherapeutic microbe to address skin barrier dysfunction associated with ichthyosis vulgaris. Through this work, we recognized the broader commercial potential of recombinant filaggrin technology and its ability to support skin hydration and appearance. Our initial focus is the development of a cosmetic ingredient targeting the reduction of fine lines and wrinkles.

Research has shown that up to 10% of the general population and more than 50% of eczema sufferers are deficient in filaggrin, a protein naturally produced by healthy skin that plays a critical role in maintaining hydration and skin barrier function. We believe recombinant filaggrin technology may offer a differentiated approach within the growing multi-billion dollar skincare market.

We are currently conducting product optimization and ex vivo human skin studies and anticipate initiating a clinical study to evaluate the product candidate's effect on the appearance of fine lines and wrinkles. We expect to complete this study in late 2026, putting the program on track for potential partnership or commercialization as soon as 2027.